Pulmonary/Respiratory Diseases | Phase II Developments | UNITED STATES

Gossamer Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Gossamer Bio Announces Data Presentations at the Virtual European Respiratory Society International Congress 2020

Lead Product(s): GB001

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB001

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 07, 2020

Details:

Gossamer Bio will present four posters with data relevant to its GB001 and GB002 programs at the Virtual European Respiratory Society International Congress 2020.

Pharmaceutics International

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Humanetics Corporation and Pharmaceutics International Announce Partnership in Support of BIO 300 Clinical Trials in COVID-19 Patients

Lead Product(s): Genistein

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO 300

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Humanetics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership August 19, 2020

Details:

Partnership will support clinical trial studies of BIO 300 in COVID-19 patients.

AnaptysBio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Anaptysbio Announces Second Quarter 2019 Financial Results and Provides Pipeline Updates

Lead Product(s): Etokimab

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ANB020

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 08, 2020

Details:

AnaptysBio presented full data from its Phase 2a proof-of-concept clinical trial of etokimab in adult patients with severe eosinophilic asthma at the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.

Gossamer Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Gossamer Bio Announces Data Presentations at the American Thoracic Society 2020 Virtual Conference

Lead Product(s): GB001

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB001

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 05, 2020

Details:

Gossamer Bio will present four posters with data relevant to its GB001 and GB002 programs at the American Thoracic Society 2020 Virtual Conference.

Partner Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Partner Therapeutics Announces $35 Million Deal with U.S. DOD for Advanced Development and Emergency Use of Leukine for COVID-19

Lead Product(s): Sargramostim

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Leukine

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: U.S. Department of Defense

Deal Size: $35.0 million Upfront Cash: Undisclosed

Deal Type: Agreement August 04, 2020

Details:

Funding will support two clinical studies of inhaled Leukine® (sargramostim, rhu-Granulocyte Macrophage-Colony Stimulating Factor “GM-CSF”) in patients with COVID-19 associated acute hypoxemia.

Aerpio Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for Treatment of ARDS in COVI...

Lead Product(s): Razuprotafib

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AKB-9778

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: MTEC

Deal Size: $5.1 million Upfront Cash: Undisclosed

Deal Type: Funding August 04, 2020

Details:

Aerpio is developing a selective small molecule inhibitor of vascular endothelial protein tyrosine phosphatase, razuprotafib (AKB-9778), that restores Tie2 pathway activation in endothelial cells to stabilize blood vessels during vascular injury and inflammation.

Humanetics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Humanetics Corporation Receives Funding from NIAID to Test Drug in COVID-19 Patients

Lead Product(s): Genistein

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding July 23, 2020

Details:

Funding will be used to conduct a placebo-controlled double-blind study to understand if 12 weeks of BIO 300 can mitigate lasting COVID-19 effects in the lungs and improve the quality of life for patients.

SarcoMed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Protalix BioTherapeutics Inks Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis

Lead Product(s): Alidornase alfa

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PRX–110

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Protalix BioTherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 23, 2020

Details:

The arrangement, if consummated, would relate to the development and commercialization of PRX–110, or alidornase alfa, for the treatment of Pulmonary Sarcoidosis and related diseases.

Angion Biomedica

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Angion Initiates Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

Lead Product(s): ANG-3777

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ANG-3777

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 08, 2020

Details:

The Phase 2 trial is a multicenter, prospective, randomized, double-blind, placebo-controlled trial to assess safety and efficacy of ANG-3777 in patients hospitalized with confirmed COVID-19 pneumonia.

Tenax Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules

Lead Product(s): Levosimendan

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: H.C. Wainwright & Co

Deal Size: $8.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering July 06, 2020

Details:

Tenax currently intends to use the net proceeds from the offerings to further its clinical trials of levosimendan, for research and development and general corporate purposes, including working capital and potential acquisitions.

Find

Find Drugs for Pulmonary/Respiratory Diseases in Phase II Clinical Development in UNITED STATES

United States

Product Type

Companies

Gossamer Bio

Gossamer Bio Announces Data Presentations at the Virtual European Respiratory Society International Congress 2020

Pharmaceutics International

Humanetics Corporation and Pharmaceutics International Announce Partnership in Support of BIO 300 Clinical Trials in COVID-19 Patients

AnaptysBio

Anaptysbio Announces Second Quarter 2019 Financial Results and Provides Pipeline Updates

Gossamer Bio

Gossamer Bio Announces Data Presentations at the American Thoracic Society 2020 Virtual Conference

Partner Therapeutics

Partner Therapeutics Announces $35 Million Deal with U.S. DOD for Advanced Development and Emergency Use of Leukine for COVID-19

Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for Treatment of ARDS in COVI...

Humanetics

Humanetics Corporation Receives Funding from NIAID to Test Drug in COVID-19 Patients

SarcoMed

Protalix BioTherapeutics Inks Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis

Angion Biomedica

Angion Initiates Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

Tenax Therapeutics

Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules